Patients Progressing on an AI ± CDK4/6 Inhibitors: From Biomarkers to Treatment Strategies

<p><span lang="EN-US" style= "font-size: 11.0pt; line-height: 115%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;" xml:lang="EN-US">Did you know that the prevalence of acquired <em style="mso-bidi-font-style: normal;">ESR1</em> mutations increases after exposure to endocrine therapy?</span></p> <p><span lang="EN-US" style= "font-size: 11.0pt; line-height: 115%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;" xml:lang="EN-US">Cr...